Document Detail


A study on strategies for improving growth and body composition after renal transplantation.
MedLine Citation:
PMID:  20151158     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Allograft function and metabolic effects of four treatment regimens, namely, methylprednisone (MP) standard dose (MP-STD), deflazacort (DFZ), MP-late steroid withdrawal (MP-LSW), and MP-very low dose (MP-VLD), were evaluated in prepubertal patients. MP was decreased by month 4 post-transplantation to 0.2 mg/kg/day in MP-STD and DFZ patients and to <0.1 mg/kg/day in MP-LSW and MP-VLD patients. Starting in month 16 post-transplant, MP was switched to DFZ in the DFZ group and totally withdrawn in the MP-LSW group. Creatinine clearance diminished in the MP-STD and MP-LSW groups from 77 +/- 6 to 63 +/- 6 ml/min/1.73 m(2)and from 103 +/- 5 to 78 +/- 3 ml/min/1.73 m(2), respectively (p < 0.01 and p < 0.001, respectively). Height increased >0.5 SDS only in the MP-LSW and MP-VLD groups. The body mass index and fat body mass for height-age increased only in the MP-STD patients (p < 0.05 and p < 0.01, respectively). Fat body mass decreased in the DFZ group (p < 0.05), total cholesterol and LDL-cholesterol increased in the MP-STD group, while LDL-cholesterol and total cholesterol/HDL-cholesterol ratio decreased in the DFZ group (p < 0.01). Lumbar spine bone mineral density (BMD) for height-age showed an increase in the MP-LSW and MP-VLD groups (p < 0.01). Our data suggest that MP-LSW and MP-VLD strategies improve linear growth, BMD, the peripheral distribution of fat, and preservation of the bone-muscle unit and maintain the normal lipid profile. The MP-LSW patients had a concerning rate of acute rejections and graft function deterioration in prepubertal patients.
Authors:
Jorge R Ferraris; Titania Pasqualini; Guillermo Alonso; Susana Legal; Patricia Sorroche; Ana Galich; Paula Coccia; Lidia Ghezzi; Ver?nica Ferraris; Liliana Karabatas; Clara Guida; H?ctor Jasper
Related Documents :
15706008 - A cholesterol-rich diet accelerates bacteriologic sterilization in pulmonary tuberculosis.
7987528 - A prospective randomized cross-over comparison of mono- and biphasic defibrillation usi...
20669318 - Low-protein and protein-redistribution diets for parkinson's disease patients with moto...
318898 - Dreaming, fenfluramine, and vitamin c.
8378218 - Divergent selection for growth in japanese quail under split and complete nutritional e...
9007178 - Does lipid infusion affect bile composition in humans?
Publication Detail:
Type:  Journal Article     Date:  2010-02-12
Journal Detail:
Title:  Pediatric nephrology (Berlin, Germany)     Volume:  25     ISSN:  1432-198X     ISO Abbreviation:  Pediatr. Nephrol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-02-24     Completed Date:  2010-06-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8708728     Medline TA:  Pediatr Nephrol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  753-62     Citation Subset:  IM    
Affiliation:
Servicio de Nefrolog?a Pedi?trica, Hospital Italiano, Buenos Aires, Argentina. jorge.ferraris@hospitalitaliano.org.ar
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Body Composition / physiology*
Bone Density / drug effects,  physiology
Child
Child, Preschool
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Graft Rejection / chemically induced
Growth / physiology*
Growth Disorders / physiopathology,  prevention & control*,  rehabilitation
Humans
Immunosuppressive Agents / therapeutic use
Kidney Transplantation / adverse effects*,  rehabilitation
Lumbar Vertebrae / drug effects,  metabolism
Male
Methylprednisolone / therapeutic use
Postoperative Complications / prevention & control,  rehabilitation
Pregnenediones / therapeutic use
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Pregnenediones; 14484-47-0/deflazacort; 83-43-2/Methylprednisolone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  New therapies: calcimimetics, phosphate binders and vitamin D receptor activators.
Next Document:  IgG subclasses and complement pathway in segmental and global membranous nephropathy.